Neoadjuvant Therapy of Darolutamide Plus ADT for High Risk Prostate Cancer

Summary

The purpose of this study is to determine if treatment with Darolutamide plus androgen deprivation therapy (ADT) before radical prostatectomy (RP) with pelvic lymph node dissection (pLND) in participants with high-risk localized or locally advanced prostate cancer results in an improvement in pathological complete response (pCR) rate and pathological tumor volume with minimal residual disease (MRD)) as compared to ADT.

Eligibility

Inclusion Criteria:

* Patients must be ≥ 18 and ≤75 years of age.
* All patients must have a histologically or cytologically diagnosis of prostate cancer and must be eligible for radical prostatectomy.
* Eastern Cooperative Oncology Group (ECOG) Performance Status score ≤1.
* All patients must complete mpMRI or 68Ga-PSMA PET / CT before and after neoadjuvant treatment.
* All patients must undergo thorough tumor staging and meet one of the following criteria: 1. multi-parameter MRI or PSMA PET / CT shows clinical staging of primary tumor ≥ cT2c or cN+or locally advanced, 2. Gleason score of primary tumor ≥ 8, 3. prostate specific antigen (PSA) ≥20 ng/ml.
* Patients must have adequate organ function as defined by the following criteria(within 28 days prior to registration):

white blood cell (WBC) ≥ 4.0 × 109 / L platelets≥ 100 × 109 / L hemoglobin ≥ 9 g / dL international normalized ratio (INR) \< 1.5. total bilirubin (TBIL)≤1.5 x upper limit of normal (ULN) SGOT (AST) and SGPT (ALT) ≤ 2.5 x ULN serum creatinine ≤2×ULN

* Patients must participate voluntarily and sign an informed consent form (ICF), indicating that they understand the purpose and required procedures of the study, and are willing to participate in. Patients must be willing to obey the prohibitions and restrictions specified in the research protocol.

Exclusion Criteria:

* clinical or radiological evidence of regional or extra-regional lymph node metastases or bone metastases or visceral metastases.
* Prior androgen deprivation therapy (medical or surgical) or focal treatment of prostate cancer or prostate cancer radiotherapy or prostate cancer chemotherapy.
* severe or uncontrolled concurrent infections.
* New York Heart Association Class III or IV congestive heart failure at the time of screening.
* uncontrolled severe hypertension, persistent uncontrolled diabetes, oxygen-dependent lung disease, chronic liver disease, or HIV infection.
* Patients with mental illness, mental disability or inability to give informed consent are not eligible.
* Patients have had other malignancies other than prostate cancer in the past 5 years, but cured basal cell or squamous cell skin cancers can be enrolled.

Conditions2

Interventions2

Related trials

• A Study to Learn How Well a Combination of Darolutamide and Androgen Deprivation Therapy (ADT) Works as a Treatment Before Surgery for Men Who Have High-risk Localized Prostate Cancer. — Bayer
• Darolutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC) — Swiss Cancer Institute
• Docetaxel or Cabazitaxel With or Without Darolutamide in mCRPC — Erasmus Medical Center
• Observational Study of the Effectiveness of Funded Drugs for Genitourinary Tumors. — Spanish Oncology Genito-Urinary Group
• ProBio: A Biomarker Driven Study in Patients With Metastatic Prostate Cancer — Karolinska Institutet
• Study Evaluating the Efficacy and Safety of Darolutamide and Stereotactic Dose Escalated Radiotherapy in Patients With Localized Prostate Cancer and High-risk Features of Relapse — UNICANCER
• TT-702 in Patients With Advanced Solid Tumours. — Cancer Research UK
• Treatment of High-Risk Prostate Cancer Guided by Novel Diagnostic Radio- and Molecular Tracers — Cancer Research Antwerp

Browse More Trials